Matching Adjusted Indirect Comparisons of Personalized Prophylaxis with Simoctocog Alfa Versus Efmoroctocog Alfa, Damoctocog Alfa Pegol and Rurioctocog Alfa Pegol in Patients with Hemophilia a

被引：0
|
作者：
Kessler, Craig M. [1 ]
Tiede, Andreas [2 ]
机构：
[1] Georgetown Univ, Sch Med, Washington, DC USA
[2] Hannover Med Sch, Clin Haematol Haemostaseol Oncol & Stem Cell Tran, Hannover, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162205
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2755 / 2756
页数：2
相关论文
共 50 条
  • [31] Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A
    Sun, Shawn X.
    Frick, Andrew
    Balasa, Vinod
    Roberts, Jonathan C.
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (10) : 943 - 950
  • [32] EXPERIENCE WITH RURIOCTOCOG ALFA PEGOL (ADYNOVI ®) IN REAL LIFE AT THE PEACE UNIVERSITY HOSPITAL
    Alvarez Roman, M. T.
    Garcia Barcenilla, S.
    Martin Salces, M.
    Rivas Pollmar, M., I
    Gutierrez Alvarino, M.
    Justo Sanz, R.
    Jimenez Yuste, V
    HAEMATOLOGICA, 2019, 104 : 114 - 115
  • [33] A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
    Aledort, Louis
    Milligan, Scott
    Watt, Maureen
    Booth, Jason
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 492 - 503
  • [34] Damoctocog Alfa Pegol: A Review in Haemophilia A (vol 79, pg 1147, 2019)
    Paik, Julia
    Deeks, Emma D.
    DRUGS, 2019, 79 (13) : 1495 - 1495
  • [35] CANADIAN CLINICAL EXPERIENCE ON SWITCHING FROM OCTOCOG ALFA TO EXTENDED-HALF-LIFE FVIII DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA A
    Iorio, A.
    Matino, D.
    Decker, K.
    Iserman, E.
    Keepanasseril, A.
    Germini, F.
    Chan, A. K. C.
    Walsh, L.
    HAEMOPHILIA, 2022, 28 : 43 - 43
  • [36] A RETROSPECTIVE STUDY OF THE IMPACT OF SWITCHING PATIENTS WITH HAEMOPHILIA A TO RURIOCTOCOG ALFA PEGOL OR EMICIZUMAB IN US PRACTICE
    Sun, S. X.
    Frick, A.
    HAEMOPHILIA, 2021, 27 : 39 - 39
  • [37] Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a
    Shima, Midori
    Taki, Masashi
    Shirayama, Rie
    Matsushita, Tadashi
    Nishida, Yasuharu
    Nagao, Azusa
    Ogawa, Yoshiyuki
    Kawasugi, Kazuo
    BLOOD, 2022, 140 : 11304 - 11305
  • [38] CLINICAL OUTCOMES FOLLOWING PROPHYLAXIS WITH RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A: REAL-WORLD OBSERVATIONAL DATA FROM THE AHEAD INTERNATIONAL STUDY
    Ozelo, M. C.
    Hermans, C.
    Khair, K.
    Guillet, B.
    Guerra, R.
    Gu, J.
    Tang, L.
    Carcao, M.
    HAEMOPHILIA, 2022, 28 : 45 - 45
  • [39] Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa
    Pitance, Victoire
    Desage, Stephanie
    Lienhart, Anne
    Meunier, Sandrine
    Chamouard, Valerie
    HAEMOPHILIA, 2021, 27 (03) : E368 - E375
  • [40] FACTOR UTILISATION IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL IN THE ATHN 2 STUDY
    Journeycake, J.
    Caicedo, J.
    Cheng, D.
    Denne, M.
    Guelcher, C.
    Lattimore, S.
    Mokdad, A.
    Ragni, M.
    Recht, M.
    Sidonio, R., Jr.
    Takemoto, C.
    Tarantino, M. D.
    Watson, C.
    Neufeld, E.
    HAEMOPHILIA, 2021, 27 : 79 - 80
12345